Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CP029
- Development stage
- Preclinical
- Lead developer
- Jiangsu Changfeng Pharmaceutical
- Administration
- Inhalation
01
Overview
CP029 is a preclinical-stage pharmaceutical drug developed by CF PharmTech, Inc., a company focused on inhaled respiratory products. It is currently being investigated for its potential therapeutic applications in immune system diseases and respiratory diseases, with asthma identified as a specific active indication. As an inhaled respiratory product, its intended route of administration is likely inhalation.
Beyond the preview
Go deeper on CP029.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CP029.